Amvis Holdings (7071) Fundamentals 2026 — P/E 12.9x, Revenue Analysis | SniperIQ
Amvis Holdings (7071) is a JP-listed Healthcare company in Medical - Care Facilities with a market capitalization of ¥37.2B, trading at ¥379.00 on the JPX. This SniperIQ fundamentals page covers Amvis Holdings's valuation (P/E 12.9x, P/B 1.0x), profitability (net margin 5.6%), revenue (¥49.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Amvis Holdings's market cap?
Amvis Holdings (7071) has a market capitalization of approximately ¥37.2B, trading at ¥379.00 on the JPX. Market cap moves with the live share price.
What is Amvis Holdings's P/E ratio?
Amvis Holdings's trailing twelve-month P/E ratio is 12.9x, with a price-to-book (P/B) of 1.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Amvis Holdings?
Amvis Holdings runs a net profit margin of 5.6%, a gross margin of 27.7%, and an operating margin of 10.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Amvis Holdings generate?
Amvis Holdings reported revenue of ¥49.2B for fiscal year 2025, with net income of ¥3.7B and earnings per share (EPS) of 37.52. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Amvis Holdings pay a dividend?
Amvis Holdings offers a trailing dividend yield of about 1.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Amvis Holdings financially healthy?
Amvis Holdings carries a debt-to-equity ratio of 1.01x and a current ratio of 1.17x, with a market beta of 0.73. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Amvis Holdings a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Amvis Holdings (7071) the key facts are: market cap ¥37.2B, P/E 12.9x, revenue ¥49.2B, 52-week range 319-845. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Amvis Holdings's full fundamentals live
Get Amvis Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.